Comprehensive Chromosome Analysis for Embryo Genetic Screening
PGT-FAST is a preimplantation genetic test performed before embryo transfer during IVF. By analyzing embryonic cells, the test evaluates the chromosomal status of embryos and detects abnormalities that may affect pregnancy development. The test allows for the analysis of all 24 chromosomes in the embryo, identifying numerical chromosomal abnormalities, also known as aneuploidy. These abnormalities can lead to serious genetic syndromes or prevent normal embryo development.
In addition, PGT-FAST can detect large structural chromosomal abnormalities, such as deletions or duplications of 5Mb or larger. These abnormalities may be associated with genetic syndromes that impact the health and development of the child. Embryo genetic screening provides fertility specialists with scientific evidence to select embryos with normal chromosomal complements, thereby increasing implantation rates and improving IVF treatment outcomes.
Significantly Reduced Turnaround Time
One of the most notable features of PGT-FAST is its ability to significantly shorten analysis and reporting time. The optimized process allows results to be delivered within 15 hours from sample analysis. Rapid turnaround time offers practical benefits for both fertility centers and patients. Physicians can access embryo genetic results more quickly, enabling timely and appropriate clinical decisions during treatment. For many couples undergoing IVF, a shorter waiting period also helps reduce psychological stress and provides greater control over their treatment plan.
Application of Next-Generation Sequencing Technology
PGT-FAST is based on Next Generation Sequencing (NGS), one of the most advanced and accurate genetic analysis technologies available today. The sequencing system used in this test is based on the Illumina platform (USA), combined with specialized genetic data analysis software, enabling highly accurate detection of abnormalities. The test achieves high sensitivity and specificity, ensuring reliable results for embryo genetic analysis. Utilizing modern analytical technologies not only improves test accuracy but also optimizes processes and reduces turnaround time.
The introduction of PGT-FAST represents another step forward in expanding Eurofins GENTIS’ genetic testing ecosystem in the field of assisted reproduction. This new testing solution is expected to provide fast, accurate, and efficient options for IVF centers and families seeking the opportunity to welcome healthy babies.
In an era where reproductive medicine increasingly emphasizes genetic factors, the development of advanced testing solutions like PGT-FAST is expected to further enhance treatment quality and help families move closer to their dream of becoming parents.
